For bfp detection via CRISPR–Chip, target HEK-BFP and non-target HEK genomic materials lacking the bfp sequence were utilized. Briefly, HEK-BFP DNA was extracted from bfp-transduced HEK293T cells (PureLink Genomic DNA Mini Kit; Thermo Fisher Scientific) and purified (QIAquick PCR Purification Kit; Qiagen) according to the manufacturer’s instructions and published protocol36 (link). For analysis of DMD-associated mutations via CRISPR–Chip, human genomic samples from both healthy male and DMD male patients were purchased with certificate of analysis from the Coriell Institute for Medical Research. DMD samples presented in this study carried previously identified large-scale fragment deletions: A (NA07691)44 (link), B (NA03780)44 (link), C (NA03782)44 (link), D (NA04100)44 (link), E (NA05126)44 (link) and F (NA04364)44 (link). Healthy samples—H1 (NA22264), H2 (NA22807) and H3 (NA03798)—were also validated for the presence of target exons (see Supplementary Fig. 14). The concentration of genomic material was routinely measured before incubation with CRISPR–Chip using Nanodrop (Infinite M200 NanoQuant; Tecan).